C2 Therapeutics

He has extensive experience creating high performing teams, devising successful go-to-market strategies, driving business models and surpassing growth and sales targets. Barrett’s esophagus and squamous dysplasia are both conditions in which the epithelial cells in the lining of the esophagus abnormally change to create pre-cursor lesions. If left untreated, these lesions can progress to esophageal cancer in a few patients. The C2 CryoBalloon Ablation System provides the interventional endoscopist with a way to deliver a targeted dose of cryogen to ablate these tissues immediately.

• In 25 of 26 patients who had undergone follow-up endoscopy, complete eradication was seen in completely of BE islands that had been completely ablated during CbFAS treatment; No buried glands were entirely on biopsy.
• The device will be available for commercial use initially in parts of western Europe, C2 Therapeutics said.
• This web site includes data published by the Centers for Medicare and Medicaid Services on June 28, 2019.
• In europe, The CryoBalloon Ablation System is indicated to ablate unwanted tissue in the gastrointestinal tract, including treatment of Barrett’s Esophagus and squamous dysplasia with application of extreme cold.

This database is not intended to provide medical advice and patients should check with their doctors to determine if it contains relevant information and if such information has medical implications for them. MassDevice may be the leading medical device news business journal telling the stories of the devices that save lives. The C2 CryoBalloon Ablation System eliminates the need for precise sizing, multiple deployment steps and costly generators.
The technology uses an affordable and simple to use platform of a conformable and self-sizing balloon which you can use through the endoscope as a primary, curative therapy. The acquisition of C2 Therapeutics is poised to dramatically expand Pentax from a recognised diagnostic optical technology right into a therapeutic one with a global impact”.

Sanofis Sarclisa Treatment Combination Shows More Positive Data On Multiple Myeloma

C2 Therapeutics was founded in 2007 to address the limitations of current Barrett’s esophagus treatment options. Headquartered in Redwood City, California, C2 is a privately held company whose Coldplay Systems set a new standard for simplicity in the endoscopic ablation of Barrett’s Esophagus. The technology comprises a through-the-scope, highly compliant balloon catheter that’s simultaneously inflated and cooled by an inert cryogen delivered by way of a small disposable handheld unit. The C2 Coldplay CryoBalloon™ Focal Ablation System eliminates the need for precise sizing, multiple deployment steps, and controller units. Of the 26 patients evaluated, 13 had low-grade dysplasia , 5 had high-grade dysplasia , and 8 had early carcinoma; 20 patients had undergone radiofrequency ablation ahead of entering the study.

of data points on vendors, products, partnerships, and patents to greatly help your team find their next technology solution. PitchBook is a financial technology company that delivers data on the capital markets. Halsey previously served as senior vice president, Strategy and Business Development, for Varian Medical Systems, the $7 billion global developer/provider of cancer therapy.

C2 Therapeutics Announces Leadership Team Expansion

In 25 of 26 patients who had undergone follow-up endoscopy, complete eradication was observed in 100 percent of BE islands that had been completely ablated during CbFAS treatment; No buried glands were entirely on biopsy. The median cryoablation time was 4 minutes and mean overall endoscopy duration was 13 minutes. Abstract #Mo2021, “Efficacy and Safety of the CryoBalloon Focal Ablation System for the Eradication of Dysplastic Barrett’s Esophagus Islands”, describes preliminary results from a continuing, prospective trial of CbFAS in patients with dysplastic Barrett’s esophagus or residual BE after removal of early cancer. In this study, regions of dysplastic tissue, referred to as BE islands, or a band of BE islands were treated follow-up endoscopy performed 6-8 weeks following treatment.
C2 Therapeutics was founded in 2007 to handle the limitations of current Barrett’s esophagus treatment options. Headquartered in Redwood City, they develop and commercialize the CryoBalloon Ablation technology for the treating Barrett’s Esophagus and squamous dysplasia.

C2 Therapeutics is targeted on eliminating pre-cancerous conditions and adjunctive treatment in cancer in gastroenterology and pulmonary. C2 Therapeutics is really a medical device company developing Cryoballoon Ablation, which is important in cardiac fibrilation. For PENTAX Medical, this acquisition expands the company’s role in the gastroenterology suites around the globe from being a provider of advanced imaging for diagnostics, to now providing advanced therapeutic solutions aswell. The business says the systems provides endoscopists with an increase of options to get rid of cancer precursor Barrett’s Esophagus and improve patient outcomes. BE develops because of chronic injury from gastroesophageal reflux disease. Over time, the esophageal lining is replaced with abnormal cells, putting patients at greater threat of developing cancer.
Headquartered in Redwood City, they develop and commercialize the CryoBalloon™ Ablation technology for the treating Barrett’s Esophagus and squamous dysplasia. Medical devices help to diagnose, prevent and treat many injuries and diseases. We have been not suggesting or implying that any companies or other entities included in the International Medical Devices Database engaged in unlawful conduct or otherwise acted improperly.
Medicine says, “Esophageal adenocarcinoma is on the rise in the West while squamous esophageal cancer remains rampant in Asia and Africa. Nevertheless, using various modern endoscopic high-resolution techniques we have been increasingly recognizing early and potentially curable esophageal cancer. The usage of the CryoBalloon™ allows the endoscopist to noninvasively eradicate pre-cancerous esophageal dysplasia by freezing the abnormal tissue safely, comfortably and effectively.

In 1999, she co-founded Asante Partners, a strategic advisory firm centered on medtech mergers, financings and corporate partnerships. At Asante, Halsey led many successful exits, including the sale of Surpass Medical to Stryker Corporation, Chestnut Medical to ev3/Covidien plc and CryoCath to Medtronic plc. Should you be at an office or shared network, it is possible to ask the network administrator to run a scan across the network searching for misconfigured or infected devices. C2 Therapeutics produces the C2 CryoBalloon Ablation System for the endoscopic ablation of unwanted tissue such as for example Barrett’s esophagus. Residual Barrett’s esophagus was observed during follow-up in 2 patients, C2 Therapeutics said, with one patient having received incomplete ablation and the other experiencing a 50% reduction in BE size post-ablation. The CB Insights tech market intelligence platform analyzes millions of data points on capital raising, startups, patents , partnerships and news mentions to help you see tomorrow’s opportunities, today. It’s events, podcasts, webinars and one-on-one exchanges of ideas & insights.